Key facts
- Genialis’s last known valuation is $37.0M (Jan 2023).
- It has raised $16.4M across 2 recorded rounds; the latest was Seed Round ($700K) in Dec 2025.
- Notable investors include Redalpine, Rajeev Surati, Debiopharm Innovation Fund, Drew Volpe, First Star Ventures — 9 tracked in total.
- Genialis has filed 1 Form D with the SEC, most recently Jan 2023 ($11.4M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Genialis
Funding rounds
2 roundsAbout Genialis
Developer of an AI-driven cancer biology platform designed to predict how therapies will perform in patients. The company offers an RNA-based foundation model trained on large-scale tumor data, enabling pharmaceutical developers, diagnostics teams, and clinicians to evaluate drug behavior, improve test development, and support more informed treatment decisions.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Employees
- 25
- Website
- genialis.com/
- Ownership
- Privately Held (backing)
Genialis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genialis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genialis in its N-PORT filings yet. We sweep new filings monthly.